Huons Decides to Absorb Subsidiary Huons Lab - Merger Ratio 1:0.4257, 3.83M New Shares (24.20% Dilution)
- Huons decided to absorb its subsidiary Huons Lab with a merger ratio of 1:0.4256893, issuing 3,825,327 new shares (24.20% dilution)
- Huons Lab is an unlisted biopharmaceutical R&D company with negative equity of KRW -1.8 billion and net loss of KRW 10.2 billion as of end-2025
- The merger aims to strengthen new drug pipelines and build a full value chain for biopharmaceuticals to enhance global competitiveness
- The appraised value per share is KRW 34,062 for Huons and KRW 14,500 for Huons Lab, deemed fair by external evaluator Ichon Accounting
- The expected buyback price for appraisal rights is KRW 32,886; Huons may cancel the merger if total buyback exceeds KRW 30 billion
- Stock price recently rose from KRW 26,150 in March 2026 to KRW 34,800 in May 2026
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Report on Major Matters (Decision on Company Merger) (Major Management Matters of Subsidiary)
- Company: Huons Global (084110)
- Submission: Huons Global Co., Ltd.
- Receipt: 05-18-2026
- Under KRX KOSDAQ Market Division